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ATR (ataxia telangiectasia and Rad-3-related) is a protein
kinase thatmaintains genome stability and halts cell cycle phase
transitions in response toDNAlesions that blockDNApolymer-
ase movement. These DNA replication-associated features of
ATR function have led to the emergence of ATR kinase inhibi-
tors as potential adjuvants for DNA-damaging cancer chemo-
therapeutics. However, whether ATR affects the genotoxic
stress response in non-replicating, non-cycling cells is currently
unknown.We therefore used chemical inhibition of ATR kinase
activity to examine the role of ATR in quiescent human cells.
Although ATR inhibition had no obvious effects on the viability
of non-cycling cells, inhibition of ATR partially protected non-
replicating cells from the lethal effects of UV and UVmimetics.
Analyses of various DNA damage response signaling pathways
demonstrated that ATR inhibition reduced the activation of
apoptotic signaling by these agents in non-cycling cells. The
pro-apoptosis/cell death function of ATR is likely due to tran-
scription stress because the lethal effects of compounds that
block RNApolymerasemovement were reduced in the presence
of an ATR inhibitor. These results therefore suggest that
whereasDNApolymerase stalling at DNA lesions activates ATR
to protect cell viability and prevent apoptosis, the stalling of
RNA polymerases instead activates ATR to induce an apoptotic
formof cell death innon-cycling cells. These results have impor-
tant implications regarding the use of ATR inhibitors in cancer
chemotherapy regimens.
Ultraviolet (UV) photoproducts and other bulky DNA
lesions block the progression of DNA and RNA polymerases
and lead to the activation of various DNA damage responses
that are regulated by the action of the ataxia telangiectasia and
Rad-3-related (ATR)3 protein kinase. For example, in response
to DNA polymerase stalling and uncoupling from DNA heli-
case activity (1), ATR is thought to be recruited to single-
stranded regions of DNA where it promotes a number of DNA
metabolic processes that maintain genomic integrity (2–6),
including replication fork stabilization, DNA synthesis and
lesion bypass, homologous recombination, replication origin
firing, and cell cycle delay. The importance ofATRkinase activ-
ity in these responses in replicating cells is evidenced by the fate
of cells in which the catalytic activity of ATR has been geneti-
cally or pharmacologically inhibited following replication
stress, which include apoptosis and entry into catastrophic
mitoses (7–10). Thus, ATR helps replicating cells cope with
DNA damage and replication stress by facilitating cellular pro-
cesses that maintain genomic stability and avoid cell death.
Given these features of ATR, there has been great interest in
the development and use of selective small-molecule inhibitors
of ATR kinase activity in cancer chemotherapy regimens in
conjunction with compounds that damage DNA and generate
replication stress (11–13). For example, several studies have
shown that ATR inhibition sensitizes cancer cells to cell killing
by ionizing radiation and common cancer chemotherapeutic
drugs, including platinum compounds and topoisomerase
inhibitors (14–21). Through a relatedmechanism, ATR inhibi-
tion has also been implicated in preventing skin carcinogenesis
by promoting the death of cells exposed to environmental car-
cinogens such asUV light (22–24). Thus, the general consensus
view is thatATRprotects cells fromDNAdamage and thatATR
inhibition increases the likelihood that DNA damage will result
in cell death.
However, the stalling of DNA polymerases by UV photo-
products and other bulky DNA lesions only takes place in cells
that are actively replicating their DNA, and thus the function of
ATR in response to DNA damage and transcription stress in
non-replicating, non-cycling cells is not known. Although pre-
vious studies have indicated that ATR can be activated in non-
cycling cells in response to DNA repair intermediates (25–32)
and in response to the stalling of RNA polymerase (33–35), the
functional significance of ATR in these contexts in non-cycling
cells has not been examined.
Here, we unexpectedly found that ATR inhibition actually
protects non-cycling cells exposed to UV, UV mimetics, and
other inducers of transcription stress from undergoing an apo-
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ptotic form of cell death. This finding differs significantly from
the anti-apoptotic functions of ATR in replicating and cycling
cells. Because most cells are in a quiescent or slowly growing
state in vivo, we believe that these results have important impli-
cations for the use of ATR kinase inhibitors in cancer chemo-
therapy protocols.
Experimental Procedures
Cell Lines—Human HaCaT keratinocytes, U2OS osteosar-
coma cells, mouse embryonic fibroblasts, and hTERT-immor-
talized normal human fibroblasts (NHF1) were cultured at
37 °C in a 5%CO2 humidified incubator inDulbecco’smodified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 6 mM L-glutamine, 100 units/ml of penicillin, and
100 g/ml of streptomycin. Cycling cells were typically plated
at 30% confluence and treated the following day. Non-cycling,
quiescent cells were plated at 40–60% confluence, grown for 2
days in normal medium until the cells reached confluence, and
then maintained for 2–3 days in DMEM containing 0.5% FBS
and penicillin/streptomycin before being subjected to experi-
mental treatments as previously described (32, 36). To expose
cells to the indicated fluences of UV radiation, media was
removed and set aside before placing the cells under a GE ger-
micidal lamp that emits primarily 254-nmUV light (UV-C) that
was connected to a digital timer. Treatment withN-acetoxy-2-
acetylaminofluorene (AAAF), camptothecin, 5,6-dichloro-
1--D-ribofuranosyl-1H-benzimidazole (DRB), and triptolide
involved adding the compound directly to the culture medium
of the cells. Cells were treated with DMSO, the ATR inhibitor
VE-821 (10M), or other kinase inhibitors for 30–60min prior
to exposure to UV or addition of the indicated drugs.
Chemicals and Reagents—AAAF was purchased from the
MRIGlobal Chemical Carcinogen Repository and resuspended
in 95% ethanol. Bromodeoxyuridine (BrdU), triptolide, DRB,
and inhibitors of the mitogen-activated protein kinases
(MAPKs) MEK1/2 (U0126), p38 (SB202190), and Jun kinase
(JNK; SP600125), the phosphoinositide 3-kinases (PI3Ks; wort-
mannin and LY294002), and AMP-dependent protein kinase
(dorsomorphin/Compound C) were obtained from Sigma.
Inhibitors of the DNA damage kinases ATR (VE-821 and
AZD6738), ataxia telangiectasia-mutated (ATM; KU-55933),
DNA-dependent protein kinase (DNA-PK; NU7441), and
Checkpoint kinase 1 (CHK1; AZD7762) were purchased from
Selleckchem. The pan-caspase inhibitor Z-VAD-FMK and
inhibitors of the mammalian target of rapamycin kinase (rapa-
mycin) andTank-binding protein 1 kinase (TBK1; BX795)were
obtained from Invivogen.
RNA Interference—Lentiviral DNA particles were generated
with HEK293T cells following co-transfection of the packaging
plasmid psPAX2 and the envelope plasmid pMD2.G with the
appropriate pLKO.1 vector and Lipofectamine 2000. Empty
and XPA shRNA-containing pLKO.1 plasmids were from the
Open Biosystems TRC1 shRNA library (37). The p53 shRNA
plasmids were fromAddgene (plasmids 25636 and 25637) (38).
Immunoblotting—Cells were washed with cold PBS, scraped
from the plate, and pelleted by gentle centrifugation. Cells were
then lysed for 20min on ice in 20mMTris-HCl, pH 7.4, 150mM
NaCl, 1mM EDTA, 1mM EGTA, and 1%Triton X-100 contain-
ing a protease inhibitor mixture (Roche Applied Science). Fol-
lowing centrifugation in a microcentrifuge for 10 min at maxi-
mum speed, the soluble cell lysates were transferred to new
tubes. For experiments examining the phosphorylation of the
histone variant H2AX, the insoluble fraction was then resus-
pended in 1 SDS-PAGE sample buffer (50 mM Tris-HCl, pH
6.8, 5% glycerol, 100 mM DTT, 1% SDS, 0.005% bromphenol
blue) and sonicated. Equal amounts of soluble or insoluble cell
lysates were separated by SDS-PAGE, transferred to nitrocellu-
lose, and then probed by immunoblotting using standard pro-
cedures. Primary antibodies included antibodies against ATR
(sc-1887), CHK1 (sc-8408), p53 (sc-6243), proliferating cell
nuclear antigen (sc-56), actin (I-19), XPB (sc-293), and XPA
(sc-853) from Santa Cruz; RPA70 (A300–421A) and phospho-
KAP1 (Ser824; A304–146A) from Bethyl Laboratories; and
CHK2 (number 2662), phospho-CHK1 (Ser345; number 2348),
phospho-CHK1 (Ser296; number 2349), phospho-CHK2
(Thr68; number 2621), phospho-p53 (Ser15; number 9284),
phospho-p53 (Ser20; number 9287), phospho-H2AX (Ser139;
number 9718), BCL2 (number 2872), cleaved caspase 3 (num-
ber 9661), poly(ADP-ribose) polymerase (PARP) (number
9542), phospho-AKT (Ser473; number 9271), phosphor-c-Jun
(Ser63, number 9261), and phospho-ERK1/2 (Thr202/Tyr204;
number 4370) from Cell Signaling Technology. All primary
antibodies were used at a 1:1000 or 1:2000 dilution in 1TBST
(50 mM Tris-HCl, pH 7.4, 135 mM NaCl, 0.1% Tween 20). Sec-
ondary antibodies included horseradish peroxidase-linked
anti-rabbit IgG (NA934V) and anti-mouse IgG (NA931V) from
GE Amersham Biosciences and anti-goat IgG (number 31402)
from Pierce. Chemiluminescence was visualized with Clarity
Western ECL Substrate (Bio-Rad) or ECL PrimeWestern blot-
ting Detection Reagent (GE Amersham Biosciences) using
a Molecular Imager Chemi-Doc XRS system (Bio-Rad).
Chemiluminescent signals within the linear range of detection
were quantified using ImageQuant software (GE Healthcare).
For each soluble lysate immunoblot, the phosphoprotein signal
was quantified and normalized to actin levels in the same pro-
tein lysate, and the maximum signal for each blot was set to an
arbitrary value of 100. All other phosphoprotein/actin ratios
were then normalized to this value for each immunoblot. We
note that actin levels did not change during the first few hours
following UV and AAAF treatment, and decreased modestly at
late time points (8–12 h) when cells began undergoing apopto-
sis. For analysis of phosphorylated H2AX, the blot was stained
with 1% Ponceau red dye (Sigma) in 1% acetic acid (v/v) prior to
blocking and immunoblotting. The membrane was then
scanned, and the total histone signal quantified for normaliza-
tion of the phospho-H2AX signals. All experiments analyzing
DNA damage response signaling were repeated 2–4 times, and
the average (and standard error) of the phosphoprotein/actin
and phospho-H2AX/total histone ratios were determined and
plotted.
Cell Survival Assays—Cell survival assays were performed
using 12- or 24-well plates, and survival was typically deter-
mined 2 days following treatment unless otherwise indicated.
Following aspiration and removal of cell culture media and
dead, floating cells and two washes with cold phosphate-buff-
ered saline (PBS), the cells were fixed for 30–60 min in cold
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100% methanol at 20 °C. Methanol was then aspirated and
replaced with 0.5% crystal violet stain (J.T. Baker) in 25%meth-
anol for 10min. The plates were then washed extensively in tap
water to remove the excess stain. After drying, images of the
stained cells were then taken on a Molecular Imager Chemi-
DocXRS system (Bio-Rad) for presentation of representative,
qualitative results. The crystal violet stain was then solubilized
in 1% SDS and the absorbance at 540 nmmeasuredwith a Spec-
traMaxM3spectrophotometer (MolecularDevices).Theabsor-
bance of the untreated sample was set to an arbitrary value of 1
for each experiment, and the treatment samples normalized to
this value. All cell survival experiments were performed at least
3 times.
Immunoslot Blot Analysis—The level of DNA synthesis in
cycling and non-cycling cells was measured with an immu-
noslot blot assay. BrdU (32.5 M) was added to the cell culture
medium 1 h prior to cell harvesting. Cells were washed in cold
PBS, scraped from the plate, centrifuged at 1,600 g in amicro-
centrifuge for 5 min at 4 °C, and then frozen on dry ice.
GenomicDNAwas then purifiedwith aQIAampDNAMini kit
(Qiagen). Genomic DNA (1 mg) was immobilized on a nitro-
cellulose membrane with a Bio-Dot SF Cell immunoslot blot
apparatus (Bio-Rad) and baked at 80 °C under vacuum for 90
min. Blots were blocked in 5% milk in PBST (phosphate-buff-
ered saline containing 0.1%Tween 20) and probedwith an anti-
BrdU antibody (Sigma, B2531). Following immunoblotting, the
blots were stained with SYBRGold (Invitrogen) to ensure equal
loading of DNA. The experiment was repeated two times, and
representative results are presented.
For the analysis of repair of (6-4)pyrimidine-pyrimidone UV
photoproducts ((6-4)PPs) (36, 39), cells were harvested at the
indicated time points following exposure to 10 J/m2 of UV.
The immunoslot blot method was similar to that described
above with the exception that BrdU was omitted from the pro-
cedure and 250 ng of genomic DNA was immobilized on the
nitrocellulose membrane. An anti-(6-4)PP antibody (Cosmo
Bio 64 M-2) was used to detect (6-4)PP presence and removal
from genomic DNA.
Detection of Excised Oligonucleotide Products of Nucleotide
Excision Repair—Nucleotide excision repair activity was visu-
alized as previously described (36, 40–43) with the following
modifications. Cells in 10-cm plates were harvested 1 h after
irradiation with 20 J/m2 of UV. Cells were lysed in 25 mM
HEPES-KOH, 100mMKCl, 12mMMgCl2, 0.5mMEDTA, 12.5%
glycerol, and 0.5% Nonidet P-40 for 20 min on ice. Following
centrifugation at 16,873 g for 30 min at 4 °C, the soluble cell
lysates were added to a new tube containing 2 g of anti-XPB
antibody (Santa Cruz sc-293) to immunoprecipitate the TFIIH-
excised oligonucleotide complexes (40, 43, 44) from the lysates.
Following a 1.5-h incubation with the XPB antibody at 4 °C,
recombinant protein A/G PLUS-agarose (Santa Cruz) was
added and themixture rotated for 2 h at 4 °C. The immunopre-
cipitates were then washed three times with lysis buffer. A frac-
tion (25%) of the immunoprecipitated material was saved for
immunoblot analysis with an anti-XPB antibody. The excised
oligonucleotide products of nucleotide excision repair were
purified from the remaining material following incubation at
55 °C for 20minwith elution buffer (50mMTris-HCl, pH 8, 250
mM NaCl, 10 mM EDTA, and 0.5% SDS) containing 50 g of
proteinase K (New England Biolabs), phenol-chloroform
extraction, and ethanol precipitation. The excised oligonucleo-
tides were resuspended in 10 l of water, and half of the DNA
was 3-end labeled for 1 h at 37 °C in a 10-l reaction containing
6 units of terminal deoxynucleotidyl transferase (New England
Biolabs), 0.25 mM CoCl2, and 20 M biotin-11-dUTP (Fermen-
tas) in 1 terminal deoxynucleotidyl transferase buffer (New
England Biolabs). Following ethanol precipitation, the biotiny-
lated, TFIIH-associated excised oligonucleotides were sepa-
rated on a 12% urea-polyacrylamide gel in 1 TBE (300 V,
30–35 min), transferred to a nylon membrane in 0.5 TBE
with a Bio-Rad Trans Blot Turbo semi-dry transfer apparatus
(25 V, 25 min), and then fixed to the membrane with a UV
cross-linker. The membrane was blocked and washed three
times for 5 min each with PBS containing 2% SDS before incu-
bation for 1 hwith a 1:100,000 dilution ofHRP-coupled strepta-
vidin (ThermoFisher Scientific) in PBS containing 0.05% SDS.
Themembrane was then washed twice for 5min each with PBS
containing 0.05% SDS, TBS containing 0.1% Tween 20, and
substrate equilibration buffer (50mMTris-HCl, pH 8.8, 150mM
NaCl). Chemiluminescent signals were visualized with Clarity
Western ECL Substrate (Bio-Rad) and using a Molecular
ImagerChemi-DocXRS system(Bio-Rad).Biotinylatedoligo-
nucleotides of known length were resolved on all gels as size
markers.
Results
UV-induced DNA Damage Signaling Exhibit Different Pro-
files in Cycling and Non-cycling Cells—Previous studies com-
paring UV-induced DNA damage signaling in cycling and non-
cycling cells have been rather limited (29, 32). Thus, to examine
this issue in greater detail and specifically the contribution of
the ATR kinase, we monitored the phosphorylation of several
key DNA damage response signaling proteins following UV
irradiation of rapidly growing, subconfluent HaCaT keratino-
cytes (cycling cells) and cells grown to confluence and main-
tained in low serum (non-cycling cells). To validate that cells
grown under these conditions were indeed cycling or non-cy-
cling, we first measured the level of DNA synthesis taking place
in the cells. As shown in Fig. 1A (top), only the cycling, sub-
confluent HaCaT cells incorporated significant amounts of
BrdU into genomic DNA. The examination of protein levels in
these two cell populations demonstrated that the DNA poly-
merase clamp protein proliferating cell nuclear antigen was
present at much higher levels in cycling cells than non-cycling
cells (Fig. 1A, bottom), which provides additional evidence that
the non-cycling cells are not actively replicating their DNA.
Importantly, a subset of other DNA damage response proteins,
including RPA and ATR, were found to be present at similar
levels in cycling and non-cycling cells.
We next exposed cycling and non-cycling cells to UV. As
expected, UV induced a rapid and robust but transient phos-
phorylation of CHK1 in the cycling cells (Fig. 1B, lanes 1–6).
CHK1 phosphorylation is the most routinely used biochemical
read-out for ATR activation, and its phosphorylation occurs on
both an ATR target site (Ser345) as well as a CHK1 autophos-
phorylation site (Ser296), which requires prior activation of the
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kinase by ATR. These phosphorylation events are required for
CHK1 to suppress replication origin firing and premature entry
into mitosis (45, 46).
In contrast, very little CHK1 phosphorylation was observed
on either site in non-cycling HaCaT cells (Fig. 1B, lanes 7–12).
However, CHK1 protein levels were nearly absent in the non-
cycling cells (Fig. 1A), consistent with previous reports in other
cell lines (29, 32). Nonetheless, this difference in phosphoryla-
tion between cycling and non-cycling cells (Fig. 1C) suggests
that the canonical ATR substrate CHK1 is not a physiological
target of ATR in non-cycling cells following UV irradiation.
Nonetheless, there are several other potential protein targets
for ATR in response to DNA damage, including the tumor sup-
pressor protein p53 (32, 47) and the histone variant H2AX (48).
Interestingly, and in striking contrast to the data for CHK1,
UV-induced phosphorylation of p53 on Ser15 and H2AX on
Ser139 were actually higher in the non-cyclingHaCaT cells than
in the cycling cells (Fig. 1, B and C). We also observed robust
phosphorylation of CHK2 (checkpoint kinase 2) and KAP1
(Krüppel-associated box-associated protein 1) in the non-cy-
cling cells. These proteins are thought to be primarily phos-
phorylated by the ATM kinase in response to double-strand
breaks in DNA (49–52). Although the elevated phosphoryla-
tion of p53may be due in part tomoderately higher levels of p53
in non-cycling cells than cycling cells (Fig. 1A), several other
proteins, including CHK2, were present at similar levels in both
cycling and non-cycling cells (Fig. 1A).
To confirm these distinct DNA damage response substrate
phosphorylation profiles in another cell line, we repeated the
experiment in cycling and non-cycling telomerase-immortal-
ized normal human fibroblasts (NHF1 cells). As shown in Fig.
1D, higher levels of phosphorylation of p53, H2AX, CHK2, and
KAP1 were observed in non-cycling cells than in cycling cells.
In addition, much less CHK1 phosphorylation was observed in
the non-cyclingNHF1 cells relative to the cycling cells (Fig. 1D).
However, as was observed in HaCaT cells, CHK1 protein was
nearly absent in the non-cycling cells (data not shown). The
residual CHK1 phosphorylation that was observed in these
experiments is likely due to incomplete growth arrest and to the
small percentage of cells that continue to cycle under condi-
tions of confluence and low serum (see Fig. 4B). We conclude
that robust DNA damage signaling occurs in non-cycling cells
following UV irradiation and that the profile of phosphoryla-
tion events is different from in cycling cells.
FIGURE 1. UV-induced DNA damage signaling exhibits different profiles in cycling and non-cycling cells. A, HaCaT cells were plated at low density and
maintained in 10% FBS (cycling) or grown to confluence and maintained in 0.5% FBS (non-cycling). DNA synthesis was determined by detecting the level of
BrdU incorporation into genomicDNA. Immunoslot blotswere stainedwith SYBRGold to ensure equal loading of genomic DNA. Results from a representative
experiment are shown. Lysates from the cycling and non-cycling cells were examined by immunoblotting with antibodies against the indicated proteins. B,
cycling and non-cycling cells HaCaTwere exposed to 10 J/m2 of UV. Lysateswere prepared from the cells at the indicated time points following irradiation and
probedwith antibodies against the indicated proteins.C, quantitation of two experiments performed as in B. Phosphoprotein signalswere normalized to actin
(or total histones, in the case of H2AX phosphorylation), and the highest phosphoprotein/actin ratio for each blot was set to an arbitrary value of 100. All other
signals were normalized to this value, and the average and S.E. are shown. D, cycling and non-cycling NHF1 cells were exposed to UV and analyzed as in B.
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ATR Contributes to DNA Damage Response Protein Phosphor-
ylation in Non-cycling Cells Exposed to UV and UVMimetics—
Although ATR activation has been suggested to occur in
non-cycling cells (25–33), its signaling function has not been
extensively examined and its bona fide substrates are not
known. Thus, to examine the role of ATR kinase activity in
DNA damage signaling in non-cycling cells, wemade use of the
highly selective ATR inhibitor VE-821 (21, 53). Consistent with
a recent report (21), this compound completely blocked UV-
induced phosphorylation of CHK1 in cycling HaCaT cells
(Fig. 2A).
We then took advantage of this inhibitor in non-cycling
HaCaT cells exposed to increasing fluences of UV radiation. As
shown in Fig. 2,B andC, ATR inhibition partially abrogated the
phosphorylation of several DNA damage response substrates,
including p53 and H2AX. However, significant levels of phos-
phorylation remained in the presence of the ATR inhibitor.
Importantly, similar results were observed when we treated
non-cycling NHF1 cells with the ATR inhibitor and then
exposed the cells to increasing amounts of UV (Fig. 2D).
To examine the activity of ATR in greater detail, we per-
formed time course experiments with 10 J/m2 of UV in non-
cycling HaCaT cells. Fig. 2, E and F, shows that the ATR inhib-
itor again partially abrogated the phosphorylation of DNA
damage response substrates p53 and H2AX. However, we note
that each substrate showed unique phosphorylation kinetics,
which are impacted in different ways by ATR inhibition. For
example, p53 phosphorylation was reduced to a significant
FIGURE 2. ATR contributes to DNA damage signaling in non-cycling cells. A, cycling HaCaT cells were treated with the ATR inhibitor (ATRi) VE-821 (10 M
ATRi) or the CHK1 inhibitor (CHK1i) AZD7762 (300 nM CHK1i) for 30min prior to irradiation with 10 J/m2 UV. Cell lysates were prepared 30min post-irradiation
and analyzed by immunoblotting. B, non-cycling HaCaT cells were treatedwith DMSO or the ATRi prior to exposure to increasing fluences of UV (0, 1, 3, 10, 30,
and 100 J/m2). Cell lysates were analyzed by immunoblotting. C, quantification of p53 and H2AX phosphorylation from three independent experiments
performed as described in B. D, non-cycling NHF1 cells were treated as in B. E, non-cycling HaCaT cells were treated with DMSO or ATRi prior to UV irradiation
(10 J/m2). Cell lysates were prepared at the indicated time points and analyzed as in B. F, quantification of results from three independent experiments were
performed as shown in E.G, non-cyclingNHF1 cells were treated as in E.H, non-cyclingHaCaT cells were treatedwithDMSOor ATRi prior to exposure to theUV
mimetic AAAF (10 M AAAF). Cells lysates were analyzed by immunoblotting. I, quantification of results from three independent experiments performed
as in H.
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extent within the first hour after UV irradiation. In contrast,
H2AX phosphorylation was reduced at all time points after UV
but continued to become phosphorylated even in the presence
of the ATR inhibitor. Importantly, similar results were
observed in non-cycling NHF1 cells (Fig. 2G).
To confirm the effects of ATR inhibition on DNA damage
signaling with another DNA damaging agent, we treated non-
cycling HaCaT cells with the UVmimetic AAAF, which gener-
ates bulky, helix distorting lesions on guanine residues in DNA
that block RNA polymerase progression (54, 55) and that like
UV photoproducts are removed from DNA by the nucleotide
excision repair system (42, 56–58). As shown in Fig. 2,H and I,
the phosphorylation of p53, KAP1, and H2AXwere all reduced
following AAAF administration in the presence of the ATR
inhibitor. Consistent with the results with UV, however, these
proteins continued to be phosphorylated to significant extents
when ATRwas inhibited. These results suggest that ATR is not
the only protein kinase that phosphorylates DNA damage sig-
naling proteins in response to UV and UV mimetics in non-
cycling cells.
ATM and ATR Both Contribute to Canonical DNA Damage
Signaling Events in UV-irradiated Non-cycling Cells—A recent
study found that UV irradiation of non-cycling cells leads to
formation of double-strand breaks inDNA in a nucleotide exci-
sion repair-dependent manner (29). This double-strand break
response was associated with the activation of ATM and the
phosphorylation of both H2AX and the more specific ATM
substrate CHK2. To confirm this previous report and examine
additional DNAdamage substrates (p53 andKAP1) in this con-
text, we treated cells with an ATR inhibitor, an ATM inhibitor,
or a combination of both inhibitors and then examined UV-
induced protein phosphorylation. As shown in Fig. 3A, the
ATM inhibitor had a more significant effect on protein phos-
phorylation than the ATR inhibitor 2 h following UV irradia-
tion in non-cycling HaCaT cells. However, near complete loss
of p53, CHK2, and KAP1 phosphorylation was only observed
when the cells were treated with both inhibitors. Time course
experiments further demonstrated a near complete loss of pro-
tein phosphorylation in the presence of both ATR and ATM
inhibitors (Fig. 3B). There appears to be a small amount of pro-
tein phosphorylation that occurs at late time points in these
cells, which may be due to DNA-PK activation in response to
double-strand break formation (59). Nonetheless, the notion
that both ATR and ATM contribute to DNA damage substrate
protein phosphorylation at early time points following irradia-
tion was supported by additional experiments in non-cycling
NHF1 cells (Fig. 3C).
The DNA lesions induced by UV and UV mimetics are
removed by the process of nucleotide excision repair, which
leaves gaps in the DNA that can be enlarged to activate ATR
(32, 60, 61) or possibly give rise to double-strand breaks that
activateATM (29). Thus, to determine hownucleotide excision
FIGURE 3.Both ATR andATM contribute to canonical DNAdamage signaling events in UV-irradiated non-cycling cells. A, non-cycling HaCaT cells were
treatedwith the indicated inhibitorsprior to irradiationwithUV.Cell lysateswereprepared2hafter irradiationandanalyzedby immunoblotting.B, non-cycling
cells were treated with DMSO or a combination of an ATR (ATRi) and ATM (ATMi) inhibitors. Protein phosphorylation was analyzed by immunoblotting at the
indicated timepoints followingexposure to10 J/m2ofUV. Thegraphson the right showquantificationsof the results inB fromthree independent experiments.
C, non-cyclingNHF1cellswere treatedas inB.D, HaCaT cellswere infectedwitheither a control vector or a vector expressinga shRNAagainst theexcision repair
factor XPA. Cell lysates from puromycin-selected cells were analyzed by immunoblotting. The cells were then exposed to UV (10 Jm2), and protein phosphor-
ylation was examined by immunoblotting.
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repair affects DNA damage signaling in non-cycling cells, we
used lentiviral shRNA to knock down the excision repair factor
XPA in HaCaT cells. As shown in Fig. 3D, the phosphorylation
of p53, Chk2, and KAP1 were all reduced in non-cycling cells
deficient in XPA. However, the residual protein phosphoryla-
tion that remains suggests that there are likely excision repair-
independentmodes of ATR andATM activation in response to
UV in non-cycling cells, which could include direct recognition
of the damage by the kinases and associated proteins (62–67) or
by stalling the RNA polymerase at UV lesions (33). Nonethe-
less, the results presented in Figs. 2 and 3 suggest that UV radi-
ation leads to protein phosphorylation events that are per-
formed at least in part by the action of the ATR kinase.
ATRHasOpposing Functions on Cell Viability in Cycling and
Non-cycling Cells Exposed to UV Mimetic DNA Damaging
Agents—Wenext wanted to determine the ultimate fate of cells
in which ATR kinase activity is inhibited during exposure to
DNAdamaging agents, whichmay allow for better definition of
possible functions of ATR in non-cycling cells. UV and UV
mimetics have the potential to cause a number of cellular
responses, including the induction of cell death pathways that
lead to a loss in cell viability. Given that ATR kinase has been
reported to be essential for cell viability and cell division (68,
69), we therefore next carried out cell survival assays to examine
how ATR inhibition affects cell viability in cycling and non-
cycling cells exposed to DNA damaging agents.
We first examined the importance of ATR kinase activity on
the viability of cells in the absence of any exogenous source of
DNA damage. Consistent with the essential nature of ATR (68,
69), HaCaT cells plated at low density and then treated with the
ATR inhibitor failed to grow and divide (Fig. 4A). In contrast,
when we treated confluent, non-cycling cells with the ATR
inhibitor, we did not observe any effect of ATR inhibition on
cell viability even after continuous treatment with the ATR
inhibitor for more than 1 week (Fig. 4B). These results indicate
that ATR kinase activity is dispensable for the viability of non-
cycling cells.
We next investigated the role of the ATR kinase on the via-
bility of cycling and non-cycling cells exposed to DNA damag-
ing agents. As shown in Fig. 4C, inhibition of ATR sensitized
cycling HaCaT cells to the killing effects of UV, which is con-
sistent with previous reports (7, 8, 10, 21). In marked contrast,
however, the inhibition of ATR in non-cycling HaCaT cells
instead protected the cells from the lethal effects of UV (Fig.
4D). Regardless of the UV dose, there were significantly more
cells that remained viable and attached to the plate following
UV when treated with the ATR inhibitor. This opposite func-
tion of ATR on survival in cycling and non-cycling cells was
even more evident and striking when we treated cycling and
non-cycling cells with the UVmimetic AAAF (Figs. 4, E and F).
To further validate that ATR inhibition protects non-cycling
cells from the lethal effects of UV, we performed additional
experiments with the UV mimetic AAAF. Time course experi-
ments showed that cell viability was higher in non-cycling cells
treatedwith theATR inhibitor for several days followingAAAF
treatment (Fig. 5A). Moreover, the protective effect of the ATR
FIGURE 4. ATR inhibition has opposing effects on viability in cycling and non-cycling cells exposed to UV and UVmimetics. A, HaCaT cells were plated
at lowdensity and then treatedwith either DMSOor ATRi. The culturemediawas replaced every 2 dayswith freshmedium containingDMSOor ATRi, and cells
were stained with crystal violet at the indicated time points to monitor cell growth. Relative cell number was determined by measuring the absorption of
solubilized crystal violet from the stained cells and by normalization to day 0, which was set to an arbitrary value of 1. B, non-cycling HaCaT cells grown to
confluence andmaintained in low serumwere treated and analyzed as in A. The cell number increased less than 2-fold over the course of 8 days, indicating a
very low level of cell proliferation under these conditions. C, subconfluent, cycling HaCaT cells were treated with DMSO or ATRi prior to exposure to the
indicated fluencesofUV. Cellswere stainedwith crystal violet 2days later, and the incorporated stainwas solubilizedandquantifiedwith a spectrophotometer.
Thedecrease in cell number is likely due to a combinationof cell death and cell cycle arrest in these cells.D, confluent, non-cyclingHaCaT cellswere treated and
analyzed as in C. E, cycling HaCaT cells were treated as in C, except that cells were instead treated with the UVmimetic AAAF. F, non-cycling HaCaT cells were
treated as in E. Representative images of the stained cells are shown above the quantitative graphs. ATRi, ATR inhibitor.
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inhibitor was evident in NHF1 cells, U2OS osteosarcoma cells,
and mouse embryonic fibroblasts (Fig. 5, B–D). These results
show that cell type and genetic background do not explain the
phenomenon ATR inhibition protects non-cycling cells from
lethality induced by UV and UV mimetics.
Because ATM is also activated following UV in non-cycling
cells, we wanted to determine whether the protective effect of
the ATR inhibitor could be seen with other inhibitors of DNA
damage response kinases. Thus, we treated cells with inhibitors
to ATR, ATM, or DNA-PK before exposure to UV and AAAF.
We found thatATM inhibition had little to no effect on viability
and that DNA-PK inhibition instead sensitized the non-cycling
cells to both UV and AAAF (Fig. 5, E and F). Given that UV
induces double-strand breaks in non-cycling cells (29) and that
these breaks are expected to be primarily repaired by non-ho-
mologous end-joining rather than homologous recombination
in non-cycling cells (59), the sensitization of non-cycling cells
to DNA-PK inhibition is perhaps expected. Moreover, these
results suggest that the ATM-dependent DNA damaging sig-
naling events shown in Fig. 3 are not essential for the short-
term viability of UV-irradiated non-cycling cells. However, a
previous report suggested that the ATM protein may be neces-
sary for non-cycling cells exposed toUV to proliferate and form
colonies once stimulated with serum (29). This result indicates
that ATM has an important function in non-cycling cells
exposed toUV, potentially related to gene expression and splic-
ing (70). Nonetheless, these results suggest that ATR functions
differently than ATM and DNA-PK in the DNA damage
response to UV and UV mimetics in non-cycling cells.
To further support a specific role for ATR inhibition in the
protection of non-cycling cells from DNA damage, we made
use of a second highly specific chemical inhibitor of ATR
(AZD6738) (11, 14). As shown in Fig. 5G, the ATR inhibitor
AZD6738 partially abrogated the lethal effects of AAAF on
non-cyclingHaCaT cells, although less efficiently than VE-821.
We next investigated the specificity of ATR inhibition on the
survival of non-cycling cells exposed to AAAF. Using inhibitors
against a panel of other cell signaling kinases that have the
potential to impact cell viability, including CHK1, MAPKs,
PI3Ks, AMP-dependent protein kinase, and mammalian target
of rapamycin kinase, we found that none of the other inhibitors
were able to protect non-cyclingHaCaT cells fromAAAF treat-
ment (Fig. 5H). We conclude that the effect of ATR inhibition
on non-cycling cells exposed toUV andUVmimetics is specific
to ATR and unlikely to be mediated by direct or indirect mod-
ulation of other cell signaling kinase cascades.
ATR Promotes Apoptotic Signaling in Non-cycling Cells in
Response to DNA Damage—To determine the mode of cell
death that is affected by ATR kinase function, non-cycling
HaCaT cells were treated with a pan-caspase inhibitor during
exposure to AAAF. As shown in Fig. 6A, caspase inhibition
partially protected the cells from the lethal effects of AAAF,
although not as well as the ATR inhibitor. These results indi-
cate that ATR promotes cell death in response to AAAF at least
in part through the regulation of apoptosis.
The induction of apoptosis is associated with the cleavage of
various cellular proteins, including the apoptotic effector
enzymeCaspase 3 and theDNArepair protein PARP.As shown
in Fig. 6, B and C, the ATR inhibitor partially abrogated the
cleavage of Caspase 3 and PARP following AAAF treatment.
Moreover, the anti-apoptotic protein BCL2, which is destabi-
lized in response to DNA damage and the induction of apopto-
sis (71), was degraded at a slower rate in response to AAAF
when cells were treated with the ATR inhibitor.
FIGURE 5. InhibitionofATRbut not other kinases protectsmammalian cells from the lethal effects ofAAAF.A, non-cyclingHaCaT cellswere treatedwith
DMSOor ATRi before exposure to AAAF. Cells were stained at the indicated timepoints followingAAAF treatment tomonitor cell survival.C andD, cell survival
analyses of non-cyclingNHF1, U2OS, andMEFswere treatedwith ATRi andAAAF. E, non-cyclingHaCaT cells were treatedwith the indicated inhibitor and then
exposed to UV. Survival was determined with crystal violet staining as previously described and normalized to non-irradiated cells. F, non-cycling cells were
treated as in E except that cells were treated with AAAF. G, non-cycling HaCaT cells were treated with DMSO or 10M of the ATR inhibitor VE-821 or AZD6738
prior to treatmentwith 20MAAAF. Cell viabilitywasmonitored 2days later by crystal violet staining.H, non-cyclingHaCaT cellswere treatedwithDMSO, ATRi
(10 M VE-821), CHK1i (1 M AZD7762), MEK1/2i (5 M U0126), p38i (20 M SB202190), JNKi (50 M SP600125), PI3Ki#1 (2 M wortmannin), PI3Ki#2 (10 M
LY294002), AMPKi (5 M dorsomorphin/Compound C), mammalian target of rapamycin kinase (mTORi (1 M rapamycin)), or TBK1i (10 M BX795) for 30 min
prior to treatment with 20 M AAAF. Cells were stained with crystal violet 1 day later. ATRi, ATR inhibitor.
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These results demonstrate that the ATR kinase promotes
(and hence ATR inhibition reduces) the activation of apoptotic
signaling in response to AAAF treatment in non-cycling cells.
We note that this dependence on ATR kinase activity differen-
tiates our findings from a recent report that a fraction of ATR
directly localizes tomitochondria to inhibit apoptosis in aman-
ner that does not require its kinase activity (72). Thus, the pro-
apoptotic function of ATR kinase described here is unlikely to
be due to a function at the mitochondria.
ATR Promotes Cell Death in Non-cycling Cells Independently
of Nucleotide Excision Repair—We next examined the mecha-
nism by which ATR inhibition protects non-cycling cells from
undergoing apoptosis in response to UV and AAAF. We first
considered that ATR may regulate the removal of bulky DNA
adducts that are induced by UV and UV mimetics and that are
removed solely by nucleotide excision repair (73, 74). However,
using a highly sensitive assay of nucleotide excision repair activ-
ity that directly measures the excision of damage-containing
DNAoligonucleotides in vivo (40–43), we observed no effect of
ATR inhibition on the initial rate of excision repair following
UV (Fig. 7A). Furthermore, when wemonitored the removal of
(6-4)PPs from genomic DNA by immunoslot blot analysis, we
observed similar repair rates in the absence and presence of the
ATR inhibitor (Fig. 7B). We conclude that the enhanced cell
viability provided by ATR inhibition in non-cycling cells is not
due to an increase in nucleotide excision repair capacity.
The removal of damaged nucleotides by the nucleotide exci-
sion repair system leaves 30-nt long gaps in DNA that can be
enlarged by Exo1 (exonuclease 1). Indeed, in vitro studies have
shown that this processing of excision gaps leads to robust acti-
vation of ATR (32). To determine whether this mode of ATR
activation is responsible for the pro-apoptotic function of ATR
in non-cycling cells exposed toUV andUVmimetics, we exam-
ined how ATR inhibition affected the viability of cells deficient
in either the excision repair factor XPA or the gap enlargement
nuclease Exo1. As shown in Fig. 7, C and D, ATR inhibition
partially rescued the viability of both HaCaT cells depleted of
XPAbyRNA interference and fibroblasts fromExo1/ knock-
outmice following treatmentwithAAAF.Weconclude that the
pro-apoptotic signaling function of ATR occurs independently
of either excision gap formation or enlargement in non-cycling
cells and that ATR inhibition does not promote repair of bulky
DNA lesions.
ATR Promotes Cell Death in Non-cycling Cells Exposed to
Transcription Inhibitors—RNA polymerase stalling at DNA
lesions has been suggested to be a strong trigger for both apo-
ptosis and the activation of ATR (33–35). We therefore next
considered whether transcription arrest by UV andUVmimet-
ics may be the signal for the pro-apoptotic function of ATR. To
FIGURE 6. ATR promotes apoptosis in non-cycling cells. A, non-cycling
HaCaT cells were treated with the indicated inhibitors prior to exposure to
AAAF. Cells were stained with crystal violet 2 days after AAAF treatment, and
representative images of the stained cells are shown. The pan-caspase inhib-
itor Z-VAD-FMK (Caspase Inh.) was added at two time points in these experi-
ments, including immediately prior to AAAF treatment and 24 h later, which
wasmore effective than a single treatment at protecting cells from undergo-
ing cell death. B, non-cycling cells were treated with DMSO or ATRi and then
exposed to AAAF. Cell lysateswere prepared at the indicated time points and
analyzed by immunoblotting with antibodies against the indicated proteins.
C, quantitation of immunoblotting data in B from three independent experi-
ments. ATRi, ATR inhibitor.
FIGURE 7. ATR inhibition protects non-cycling cells from UV and UV
mimetics in a nucleotide-excision repair-independent manner. A, non-
cycling HaCaT cells were treated with DMSO or ATRi and irradiated with 20
J/m2 of UV. Cells lysates were prepared 1 h post-irradiation, and excision
repair activity wasmonitored by detecting the excised oligonucleotide prod-
ucts that associate with the repair factor TFIIH. A fraction of the TFIIH immu-
noprecipitate was analyzed by immunoblotting for the XPB subunit of TFIIH,
and theexcisedoligonucleotideswere extracted from the remainingmaterial
and 3-end labeled with biotin for detection by chemiluminesence. B, immu-
noslot blotting was used to detect the removal of (6-4)PPs from the genomic
DNA of non-cycling cells exposed to UV. The signals from two independent
experiments were quantified and plotted in the graph. C, non-cycling HaCaT
cells infected with a lentivrus against XPA were treated with DMSO or ATRi
and then exposed to increasing concentrations of AAAF. Cell survival was
determined by crystal violet staining as previously described. D, MEFs from
Exo1/ knock-out mice were treated as described in C. ATRi, ATR inhibitor;
MEF, murine embryonic fibroblasts.
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test this hypothesis, we used several compounds that interfere
with transcription and the progression of RNA polymerases
and then examined howATR inhibition affected cell viability in
response to such treatment.
We first considered the activity of topoisomerase I, which is
required to relieve torsional stress that is generated in DNA
during transcription. As shown in Fig. 8A, ATR inhibition par-
tially protected non-cycling cells from the lethal effects of the
topoisomerase I inhibitor and cancer chemotherapeutic drug
camptothecin. Interestingly, and consistent with the opposing
function of ATR on cycling and non-cycling cell viability in
response to UV and AAAF (Fig. 4), ATR inhibition was
reported to instead potentiate the cell killing effect of camp-
tothecin in cycling cells (19).
The nucleoside analog DRB rapidly inhibits transcription
and stalls RNA polymerase II by affecting its phosphorylation
status, which prevents transition of RNA polymerase II into its
productive, elongating form during transcription (75). As
shown in Fig. 8B, the cell lethality induced by DRB in non-
cycling HaCaT cells was reduced in the presence of the ATR
inhibitor.
The natural product triptolide forms a covalent complex
with the XPB subunit of TFIIH (75, 76), which is required to
unwind DNA at promoters and activate RNA polymerase II for
transcription. Thus, although triptolide causes transcription
stress, it is thought to primarily prevent transcription initiation
and not transcription elongation and therefore acts in amanner
distinct from UV, camptothecin, and DRB, which directly stall
RNA polymerases on DNA. Consistent with this notion, ATR
inhibition had a less dramatic protective effect on cell viability
following triptolide treatment (Fig. 8C).
To validate the cell viability studies with another measure of
cell death, we examined apoptotic signaling in these cells. As
shown in Fig. 8D, a reduction in PARP cleavage was observed in
camptothecin- and DRB-treated cells exposed to the ATR
inhibitor, similar to the response to AAAF (Fig. 5). We con-
clude that transcriptional stress caused by diversemechanisms,
including bulky DNA adduct formation, torsional stress, and
RNApolymerase pausing, all lead to the activation of a pro-apo-
ptotic form of ATR kinase in non-cycling cells.
ATR Promotes Cell Death in a p53-independent Manner—
The tumor suppressor protein p53 has numerous functions in
response to DNA damage, including in the regulation of apo-
ptosis (77). Although ATR contributes to p53 phosphorylation
following exposure to UV and UVmimetics (Figs. 2 and 3), the
fact that ATR inhibition protects both p53-wild-type (NHF1,
U2OS) and p53-mutant (HaCaT) cells indicated that the pro-
apoptotic function of ATR was likely independent of canonical
p53 function.
Nonetheless, even mutant forms of p53 have been reported
to promote the survival of cancer cells (78). Thus, it was for-
mally possible that ATR regulation of p53 in HaCaT cells, in
which both alleles have mutations within the p53 binding
domain (79), contributes to the pro-survival effect of the ATR
inhibitor in non-cycling cells exposed to DNA damage and
transcription stress. We therefore used lentiviral shRNAs to
knockdown p53 expression in HaCaT cells and then exposed
the cells to the UV mimetic compound AAAF. However,
using two different shRNA constructs, the ATR inhibitor
continued to improve the viability of AAAF-treated cells
(Fig. 9A). Moreover, similar results were observed when we
knocked down p53 in U2OS cells (Fig. 9B). We conclude that
p53 is not required for the pro-apoptotic function of ATR in
non-cycling cells.
Discussion
Here we demonstrated that canonical DNA damage
response signaling shows striking differences in cycling and
non-cycling cells. Because most cells in the body are in a non-
cycling or slowly proliferating state, our findings therefore sug-
gest that studies of cellular responses to DNA damage should
consider the role of the cell proliferation state in greater detail.
We showed that this issue is particularly relevant to the func-
tion of the ATR kinase, which is known to have numerous pro-
survival roles in the cellular response to replication stress
caused by DNA damage (3–5).
However, we showed that in contrast to the widely accepted
model that ATR inhibition cells to DNA damaging agents that
cause replication stress, the opposite cellular outcome is
observed upon ATR inhibition in non-cycling cells. Inhibition
FIGURE 8.ATR inhibition protects non-cycling cells from the lethal effects of transcription stress. A, non-cycling HaCaT cells were treated with DMSO or
ATRi before treatment with increasing concentrations of the topoisomerase I inhibitor camptothecin (CPT). Cells were stained with crystal violet 1 day later
(representative images are shown), and cell survival was quantified as previously described. B, cells were treated as in A except that cells were treatedwith the
RNA polymerase II inhibitor DRB. C, cells were treated as in A except that cells were treated with the TFIIH inhibitor triptolide.D, cells were treated with DMSO
or ATRi and then exposed to 2.5 M CPT, 100 M DRB, or 300 nM triptolide for 4 h. Cell lysates were prepared and analyzed by immunoblotting. ATRi, ATR
inhibitor; CPT, camptothecin.
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of ATR instead limits the degree of apoptotic cell death in
response toUV,UVmimetics, and other agents that cause tran-
scription stress. The mechanism by which ATR promotes apo-
ptosis in response to transcription stress remains unresolved,
although our results and others (33) suggest it to be indepen-
dent of p53.However, ATRhas been reported to have hundreds
of potential substrates (80), and so additional work will be
needed to identify the pro-apoptotic target(s) of ATR in non-
cycling cells. Moreover, it will also be important to determine
the molecular mechanism of ATR activation in response to
transcription stress to determine how it differs from activation
in response to replication stress andDNA excision repair inter-
mediates (3–5).
Finally, our results also have important implications regard-
ing the use of ATR inhibitors in cancer chemotherapy regi-
mens. On the one hand, ATR inhibitors may protect normal,
non-replicating cells in various organs and tissues from some of
the adverse effects of DNA damaging cancer chemotherapies.
However, it is also possible that non-cycling cancer stem cells
or other slowly proliferating cells within tumors (81, 82)may be
less prone to undergo apoptosis during cancer treatments that
utilize an ATR inhibitor. Such treatments could give rise to
additional mutations and ultimately to new tumors thatmay be
associatedwith cancer recurrence. Thus, itmay be important to
consider these issues as ATR inhibitors progress through clin-
ical trials in human patients.
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